GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » GF Value

2seventy bio (2seventy bio) GF Value : $7.08 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-24), 2seventy bio's share price is $4.35. 2seventy bio's GF Value is $7.08. Therefore, 2seventy bio's Price-to-GF-Value for today is 0.61.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes 2seventy bio is Possible Value Trap, Think Twice.

2seventy bio  (NAS:TSVT) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

2seventy bio's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=4.35/7.08
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2seventy bio GF Value Related Terms

Thank you for viewing the detailed overview of 2seventy bio's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

2seventy bio (2seventy bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » GF Value
Comparable Companies
CARM PLX CDXS TALS ABSI PEPG DSGN ADAP CTXR TRVI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
60 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.2seventybio.com
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Executives
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philip D Gregory officer: Chief Scientific Officer POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Baird William D Iii officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Yue Tang 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Lin Wei director C/O ERASCA, INC., 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO CA 92121
Nicola Heffron officer: Chief Operating Officer 2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Marcela V. Maus director 16 RICHMOND CIRCLE, LEXINGTON MA 02421
Ramy Ibrahim director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Daniel Lynch director
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938